Last reviewed · How we verify
Ivermectin 400 µg/kg
Ivermectin binds to glutamate-gated chloride channels in parasites and some insects, causing paralysis and death of the organism.
Ivermectin binds to glutamate-gated chloride channels in parasites and some insects, causing paralysis and death of the organism. Used for Parasitic infections including onchocerciasis (river blindness), Lymphatic filariasis, Strongyloidiasis.
At a glance
| Generic name | Ivermectin 400 µg/kg |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Macrocyclic lactone antiparasitic |
| Target | Glutamate-gated chloride channels (GluCl) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Parasitology |
| Phase | Phase 3 |
Mechanism of action
Ivermectin is a macrocyclic lactone that selectively activates chloride channels in invertebrate nervous and muscular systems, leading to hyperpolarization, paralysis, and death of susceptible parasites. It has high selectivity for invertebrate channels over mammalian GABA receptors due to structural differences. The drug is widely used as an antiparasitic agent against nematodes, arthropods, and certain other parasites.
Approved indications
- Parasitic infections including onchocerciasis (river blindness)
- Lymphatic filariasis
- Strongyloidiasis
- Scabies
- Lice infestations
Common side effects
- Mazzotti reaction (fever, pruritus, rash, lymphadenitis)
- Headache
- Dizziness
- Nausea
- Abdominal pain
Key clinical trials
- Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC) (PHASE2)
- Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole (PHASE3)
- Moxidectin for LF, Cote d'Ivoire (DOLF) (PHASE3)
- Ivermectin Safety in Small Children (PHASE2)
- Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis (PHASE2)
- Evaluating Pediatric Ivermectin in Children Under 15 kg (EPIC-15) (PHASE2)
- ACTIV-6: COVID-19 Study of Repurposed Medications (PHASE3)
- Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |